Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes

Teo, Jocelyn Qi-Min; Candra, Samuel Rocky; Lee, Shannon Jing-Yi; Chia, Shannon Yu-Hng; Leck, Hui; Tan, Ai-Ling; Neo, Hui-Peng; Leow, Kenneth Wei-Liang; Cai, Yiying; Ee, Rachel Pui-Lai; Lim, Tze-Peng; Lee, Winnie; Kwa, Andrea Lay-Hoon

doi:10.1186/s13756-017-0184-1

Antimicrobial Resistance & Infection Control

Table 1 Antifungal susceptibilities of major species of Candida isolates^a

From: Candidemia in a major regional tertiary referral hospital – epidemiology, practice patterns and outcomes

Antifungal	MIC₅₀ (μg/mL)	MIC₉₀ (μg/mL)	MIC Range (μg/mL)	%S^b	%SDD/I^b	%R^b	%WT^c
C albicans (n = 62)
Fluconazole	0.5	2	≤0.12–>256	95.2	1.6	3.2	93.5
Itraconazole	0.06	0.12	≤0.015–>16	–	–	–	96.7
Posaconazole	0.015	0.06	≤0.08–>8	–	–	–	96.7
Voriconazole	≤0.008	0.03	≤0.008–>8	93.6	3.2	3.2	93.5
Anidulafungin	≤0.015	0.03	≤0.015–0.25	100	0	0	98.4
Caspofungin	0.03	0.06	0.015–4	98.4	0	1.6	98.4
Micafungin	≤0.008	0.015	≤0.008–2	98.4	0	1.6	98.4
Flucytosine	≤0.06	0.25	≤0.06–>64	–	–	–	96.7
Amphotericin B	0.5	1	≤0.12–1	–	–	–	100
C. glabrata (n = 82)
Fluconazole	16	32	1–>256	–	92.8	7.2	97.6
Itraconazole	1	1	0.12–>16	–	–	–	93.9
Posaconazole	2	2	0.12–>8	–	–	–	95.1
Voriconazole	0.5	2	0.03–>8	–	–	–	97.6
Anidulafungin	0.03	0.06	≤0.015–4	98.8	0	1.2	98.7
Caspofungin	0.12	0.12	0.03–>8	96.4	2.4	1.2	96.3
Micafungin	0.015	0.015	≤0.008–4	98.8	0	1.2	98.7
Flucytosine	≤0.06	0.12	≤0.06–0.25	–	–	–	100
Amphotericin B	1	1	0.25–2	–	–	–	100
C. tropicalis (n = 78)
Fluconazole	2	64	0.5–>256	78.2	5.1	16.7	84.6
Itraconazole	0.25	0.5	0.03–>16	–	–	–	96.1
Posaconazole	0.12	0.5	0.03–4	–	–	–	98.7
Voriconazole	0.12	4	≤0.008–>8	75.6	11.5	12.8	80.8
Anidulafungin	0.03	0.12	≤0.015–0.5	98.7	1.3	0	98.7
Caspofungin	0.03	0.06	0.015–2	98.7	0	1.3	98.7
Micafungin	0.03	0.03	≤0.008–1	98.7	0	1.3	98.7
Flucytosine	≤0.06	0.12	≤0.06–32	–	–	–	96.2
Amphotericin B	1	1	0.25–2	–	–	–	100
C. parapsilosis (n = 35)
Fluconazole	0.5	2	0.25–4	97.1	2.9	0	100
Itraconazole	0.06	0.06	≤0.015–0.12	–	–	–	100
Posaconazole	0.03	0.06	0.015–0.12	–	–	–	100
Voriconazole	0.015	0.03	≤0.008–0.6	100	0	0	97.1
Anidulafungin	0.5	2	0.12–2	100	0	0	100
Caspofungin	0.25	0.5	0.06–1	100	0	0	100
Micafungin	0.5	2	0.12–2	100	0	0	100
Flucytosine	≤0.06	0.5	≤0.06–1	–	–	–	100
Amphotericin B	1	2	0.25–2	–	–	–	80.0

S susceptible, SDD susceptible dose-dependent, I intermediate, R resistant, WT wild-type
^aMICs are only reflected for the predominant species
^bSusceptibilities were assessed based on CLSI species-specific clinical interpretative breakpoints [12]. Clinical breakpoints are not available for itraconazole, posaconazole, flucytosine and amphotericin B for all species and voriconazole for C. glabrata
^cECVs were derived from [13, 14] and [15]

Back to article page

ISSN: 2047-2994

Contact us

General enquiries: journalsubmissions@springernature.com